Fig. 6: Trametinib inhibits the growth of c-MET/sgp53 HCC cells and their xenografts. | Cell Death & Disease

Fig. 6: Trametinib inhibits the growth of c-MET/sgp53 HCC cells and their xenografts.

From: Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis

Fig. 6

A Cell viability analysis of MP cells treated with trametinib. B Gross images, tumor volume, and tumor weight of MP-derived xenografts from mice treated with trametinib and vehicles. C H&E staining and immunohistochemical staining of p-ERK in xenografts from mice treated with trametinib and vehicles. Scale bar: H&E, 500 μm (40×); p-ERK, 200 μm (100×). Student’s t-test: ***P < 0.001. H&E hematoxylin and eosin staining.

Back to article page